COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Core Insights - CollPlant Biotechnologies reported significant advancements in its regenerative and aesthetic medicine initiatives, including financial results for 2025 and updates on corporate developments [1] Financial Performance - GAAP revenues for 2025 were $2.4 million, a substantial increase from $515,000 in 2024, primarily due to a $2 million milestone payment from AbbVie [20] - GAAP gross profit for 2025 was $1.5 million, compared to a gross loss of $1.1 million in 2024 [22] - GAAP net loss for 2025 was $11.5 million, or $0.94 per share, an improvement from a net loss of $16.6 million, or $1.45 per share, in 2024 [25] Corporate Developments - The company achieved a development milestone in aesthetic medicine, triggering a $2 million payment from AbbVie [2][10] - CollPlant expanded its distribution network into North America through a partnership with a U.S.-based logistics center [8] - The company launched BioFlex, a ready-to-print rhCollagen-based kit for 3D bioprinting applications, aimed at drug discovery and tissue engineering [5][6] Product Innovations - CollPlant's rhCollagen platform was utilized to create a fully humanized 3D bioprinted skin model at Mayo Clinic, providing an alternative to animal testing [4][7] - The company refined its regenerative breast implants based on new preclinical data, showing promising outcomes in tissue integration and vascularization [11][13] Intellectual Property - CollPlant secured U.S. Patent No. 12,186,449 for its photocurable dermal filler product candidate, expected to remain in force until 2039 [14] - The company received patent allowances in South Korea and Japan for its photocurable dermal filler technology and rhCollagen-based BioInks, respectively [15][16] Cost Management - CollPlant implemented a cost-reduction plan, resulting in a 25% reduction in workforce and a decrease in operating expenses from $16.1 million in 2024 to $13.0 million in 2025 [19][23]